Platelet-rich Plasma as an Adjuvant Therapy to Crystallized Phenol in the Treatment of Pediatric Pilonidal Sinus Disease: A Prospective Randomized Controlled Trial

dc.contributor.authorAzizoglu, Mustafa
dc.contributor.authorKlyuev, Sergey
dc.contributor.authorKamci, Tahsin Onat
dc.contributor.authorOkur, Mehmet Hanifi
dc.date.accessioned2025-02-22T14:09:00Z
dc.date.available2025-02-22T14:09:00Z
dc.date.issued2025
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: This study aims to evaluate the safety and efficacy of platelet-rich plasma (PRP) as an adjuvant to crystallized phenol (CP) in treating pediatric pilonidal sinus disease (PSD). Methods: A single-center randomized controlled trial was conducted at Istanbul Esenyurt Hospital. Eighty-seven patients aged 0-18 were randomly assigned to two groups: the CP group (n = 42) and the CP + PRP group (n = 45). Upon arrival at the clinic, patients began a regimen of manual shaving and, if necessary, laser epilation every 6-8 weeks. For those with pilonidal abscesses, incision, drainage, and antibiotics were given. The treatment area was sterilized and numbed with local anesthesia. Hair removal and curettage were performed, followed by the application of crystallized phenol. In CP + PRP group, PRP injections were also administered. The procedure concluded with wound dressing and thorough disinfection. The study was registered https://clinicaltrials.gov/ (NCT06324656). Results: The CP + PRP group demonstrated significantly shorter healing times (19.4 +/- 7.88 days) compared to the CP group (30.7 +/- 12.9 days) (p < 0.001). The cosmetic score was higher in the CP + PRP group (7.42 +/- 1.61) than in the CP group (6.11 +/- 1.88, p = 0.001). CP + PRP group had lower VAS scores at measured all-time points after applications (p < 0.05 for each). Complications were comparable between the groups, with no significant differences in bleeding, infections, or skin burns (p > 0.05 for each comparison). No difference was found between groups in terms of total complication rate (p = 0.398). The success rate was higher in CP + PRP group (98%; n = 44) compared to CP group (86%; n = 36) (p = 0.039). Recurrence rates were lower in CP + PRP group (2%; n = 1) than CP group (14%; n = 6) (p = 0.039). Conclusion: The autologous PRP injection in pediatric PSD is safe. The addition of PRP to CP treatment for pediatric PSD significantly improves healing time, cosmetic outcomes, and overall success rates without increasing complication rates. This combined approach offers a promising alternative for effective and efficient treatment of PSD in children. Type of the study: Randomized controlled trial. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.en_US
dc.identifier.doi10.1016/j.jpedsurg.2024.161934
dc.identifier.issn0022-3468
dc.identifier.issn1531-5037
dc.identifier.issue1en_US
dc.identifier.pmid39307596en_US
dc.identifier.scopus2-s2.0-85204409253en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.jpedsurg.2024.161934
dc.identifier.urihttps://hdl.handle.net/11468/29752
dc.identifier.volume60en_US
dc.identifier.wosWOS:001362325500001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherW B Saunders Co-Elsevier Incen_US
dc.relation.ispartofJournal of Pediatric Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectPediatric pilonidal sinus diseaseen_US
dc.subjectPlatelet-rich plasmaen_US
dc.subjectCrystallized phenolen_US
dc.titlePlatelet-rich Plasma as an Adjuvant Therapy to Crystallized Phenol in the Treatment of Pediatric Pilonidal Sinus Disease: A Prospective Randomized Controlled Trialen_US
dc.typeArticleen_US

Dosyalar